Payment overview · 2025
General Payments
$376.07
10 reported records · 7 companies
Healthcare provider profile · identity verified
Roxana Nieto
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ODESSA, TX · NPI 1265083869
Verified facts
What the public records show
CMS Open Payments records show Roxana Nieto received $376.07 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 62.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $236.14 | 62.8% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $35.93 | 9.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.53 | 9.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.47 | 6.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.40 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.40 | 4.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.20 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.07 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $153.83 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.31 | 1 | 2025 |
Source payment records
|
|||||
| RYLAZE Normalized: rylaze |
Drug | JAZZ PHARMACEUTICALS INC. | $35.93 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 178 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 78 |
| Losartan Potassium | Losartan Potassium | 168 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 65 |
| Lisinopril | Lisinopril | 147 | 63 |
| Gabapentin | Gabapentin | 144 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 82 |
| Liothyronine Sodium | Liothyronine Sodium | 104 | 46 |
| Metformin Hcl | Metformin Hcl | 102 | 46 |
| Metformin Hcl Er | Metformin Hcl | 91 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 37 |
| Furosemide | Furosemide | 67 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 58 |
| Tramadol Hcl | Tramadol Hcl | 65 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 45 |
| Meloxicam | Meloxicam | 63 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 33 |
| Carvedilol | Carvedilol | 56 | 25 |
| Montelukast Sodium | Montelukast Sodium | 52 | 32 |
| Allopurinol | Allopurinol | 50 | 19 |
| Ozempic | Semaglutide | 47 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 20 |
| Methylprednisolone | Methylprednisolone | 41 | 39 |
| Mounjaro | Tirzepatide | 41 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 15 |
| Ezetimibe | Ezetimibe | 34 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | 15 |
| Trazodone Hcl | Trazodone Hcl | 32 | 16 |
| Celecoxib | Celecoxib | 31 | 15 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Alendronate Sodium | Alendronate Sodium | 27 | 14 |
| Omeprazole | Omeprazole | 27 | 18 |
| Potassium Chloride | Potassium Chloride | 27 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 26 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 22 |
| Azithromycin | Azithromycin | 25 | 25 |
| Eliquis | Apixaban | 24 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | 13 |
| Topiramate | Topiramate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 12 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | 11 |
| Alprazolam | Alprazolam | 18 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 13 |
| Donepezil Hcl | Donepezil Hcl | 17 | 11 |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 14 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $376.07 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, GVOKE HYPOPEN, MOUNJARO, NEXLETOL, Ozempic, RYLAZE, Rybelsus, Saxenda, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error